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Abstract The NG2 proteoglycan stimulates the prolifer-
ation and migration of various immature cell types,
including pericytes. However, the role of NG2 in mediating
pericyte/endothelial cell interaction has been less clear. In
this study, we show that pericyte-specific NG2 ablation
causes several structural deficits in blood vessels in intra-
cranial B16F10 melanomas, including decreased pericyte
ensheathment of endothelial cells, diminished formation of
endothelial junctions, and reduced assembly of the vascular
basal lamina. These deficits result in decreased tumor
vessel patency, increased vessel leakiness, and increased
intratumoral hypoxia. NG2-dependent mechanisms of
pericyte interaction with endothelial cells are further
explored in pericyte/endothelial cell co-cultures. siRNA-
mediated NG2 knockdown in pericytes leads to reduced
formation of pericyte/endothelial networks, reduced for-
mation of ZO-1 positive endothelial cell junctions, and
increased permeability of endothelial cell monolayers. We
also show that NG2 knockdown results in loss of b1 inte-
grin activation in endothelial cells, revealing a mechanism
for NG2-dependent cross talk between pericytes and
endothelial cells.
Keywords Blood vessels  Co-culture systems 
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Introduction
In addition to its importance in normal development, the
process of neovascularization is also a critical aspect of
many pathologies, including tumor growth, rheumatoid
arthritis, systemic lupus erythematosus, psoriasis, macular
degeneration, and proliferative retinopathy [1]. Neovascu-
larization involves active expansion and remodeling of
capillaries and arterioles, which represent the microvessel
equivalents of arteries. These structures are composed of
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three major elements: endothelial cells, pericytes, and the
vascular basement membrane. Interactions and signaling
between these three components are essential for micro-
vessel development during both developmental and path-
ological neovascularization [2–4]. Changes in pericyte and
endothelial cell recruitment, abnormalities in pericyte/
endothelial cell interaction, or defects in assembly of the
vascular basement membrane can all lead to alterations in
cross talk among microvessel components that affect vessel
morphogenesis, maturation, and function [2, 4–6]. Identi-
fying key molecular components of microvessels and elu-
cidating the respective roles of these molecules in
mediating interactions between microvascular elements is
therefore essential for our ability to understand deficits in
cell communication that underlie microvessel dysfunction.
A major topic of study in our laboratory has been the
role of pericytes in microvessel morphogenesis and func-
tion, with a special focus on the participation of the NG2
chondroitin sulfate proteoglycan in these processes. NG2 is
a prominent component of activated pericytes, but not
endothelial cells, in both normal and pathological micro-
vessels. The proteoglycan not only serves as one of the
most reliable pericyte markers [7, 8], but also plays
important roles in pericyte recruitment and interaction with
endothelial cells during microvessel development [9–13].
Germline ablation of NG2 in the mouse leads to deficits in
pathological retinal and corneal vascularization [12], as
well as to deficits in tumor vascularization that correlate
with slower progression of both engrafted B16F10 mela-
nomas in the brain [11] and spontaneous MMTV-PyMT
mammary tumors [10]. Tumor vessels in the NG2 null
mouse are characterized by reduced pericyte coverage of
endothelial cells and by diminished assembly of the vas-
cular basement membrane [10, 11]. Altered interactions
between these key microvessel components lead to deficits
in both pericyte and endothelial cell maturation [6], and
these changes at the cellular and structural levels lead to
decreased tumor vessel patency and increased tumor vessel
leakiness. Overall, tumors in NG2 null mice exhibit
increased levels of hypoxia, due at least in part to poor
vessel function [10, 11].
These experimental results strongly suggest that NG2 is
a key molecule in mediating cross talk between pericytes
and endothelial cells. However, our interpretation of the
results is limited by the fact that NG2 is expressed in the
tumor stroma not only by microvascular pericytes, but also
by other stromal cell types. For example, NG2 is tran-
siently expressed by macrophages in most, if not all, solid
tumors. In the case of mammary tumors, NG2 is also
expressed by adipocytes, and in brain tumors, the proteo-
glycan is expressed by oligodendrocyte progenitor cells.
Therefore, in addition to the effects of NG2 ablation on
pericyte function, it is possible that the absence of NG2
from other stromal cell types can affect their production of
factors that contribute to tumor vascularization and pro-
gression. In order to examine the pericyte-specific effects
of NG2 ablation on vascularization, we have utilized both
in vivo and in vitro models to study the effects of dimin-
ished NG2 expression on microvessel formation. In vivo,
we have used Cre/lox technology to create pericyte-specific
NG2 null mice in which we examine the properties of
microvessels in engrafted intracranial B16F10 melanomas.
Tumor vessels in these mice exhibit many of the same
deficits seen in tumor vessels in germline NG2 null mice.
In vitro, we have used siRNA technology to knock down
NG2 expression in human microvascular pericytes, fol-
lowed by examination of the ability of these cells to
interact with human endothelial cells in the assembly of
vascular networks. Compared with co-cultures of endo-
thelial cells and control pericytes, network formation is
significantly reduced in the case of NG2 knockdown
pericytes. Use of a conformationally sensitive b1 integrin
antibody has allowed us to demonstrate that NG2 knock-
down in pericytes leads to reduced b1 integrin signaling in
pericytes that correlates with loss of proliferation and
motility. In addition, pericyte-dependent b1 integrin sig-
naling in closely apposed endothelial cells is reduced by
NG2 knockdown in pericytes, providing a possible expla-
nation for the impaired morphogenesis seen in assays of
network formation. Decreased b1 integrin signaling in
endothelial cells also results in reduced formation of ZO-1-
positive intercellular junctions, leading to diminished bar-
rier function of endothelial monolayers. These results
reinforce the conclusion that NG2 expression by pericytes
is important not only for pericyte biology, but also for
pericyte interactions with endothelial cells.
Materials and methods
Cell lines
Human brain microvascular pericytes (ScienCell) and
human umbilical vein endothelial cells (HUVECs, Lonza)
were maintained, respectively, in pericyte medium (PM,
ScienCell) and endothelial basal medium-2 (EBM-2,
Lonza) containing appropriate growth supplements. NG2-
negative B16F10 melanoma cells [14] were maintained in
DMEM containing 10 % fetal bovine serum.
Animals and tumor implantation
Mice were maintained in the Sanford-Burnham Vivarium
(fully accredited by the Association for Assessment and
Accreditation of Laboratory Animal Care). All animal
procedures were performed in accordance with Office of
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Laboratory Animal Welfare regulations and were approved
by Sanford-Burnham Institutional Animal Care and Use
Committee review prior to execution. NG2 floxed mice
[15] and pdgfrb-Cre transgenic mice [16, 17] were back-
crossed to C57Bl/6 backgrounds for more than 10
generations.
Intracranial B16F10 tumors were established as previ-
ously described [6, 11]. Tumors were analyzed at 7 days
post injection. Pericyte/endothelial cell overlap, basement
membrane assembly, vessel patency, leakage, and intratu-
moral hypoxia were assessed by previously described
methods [10, 11].
Immunohistochemistry and microscopy
Pericytes, endothelial cells, and apoptotic cells were
identified by staining with combinations of 2 or 3 anti-
bodies. Pericytes were labeled with rabbit anti-NG2, gui-
nea pig anti-NG2, or rabbit anti-PDGFRb (1:100, [6, 11]).
Endothelial cells were labeled with rabbit anti-human
CD31 (1:500; Abcam) or anti-human CD31 (1:500; BD
Pharmingen) for HUVECs in culture and with hamster anti-
mouse CD31 (1:500; Pierce) or rat anti-mouse CD31
(1:500; BD Pharmingen) in the case of mouse tumors.
Endothelial cell junctions in mouse tumor vessels were
identified by labeling for ZO-1 (1:500; Invitrogen). Mac-
rophages were labeled by rat anti-F4/80 (1:500, Invitrogen)
antibody. Vascular basement membrane assembly was
assessed by labeling for collagen IV (1:500, Millipore).
Apoptotic cells were labeled with rabbit antibody against
activated caspase-3 (1:500; R&D Systems), and pericyte
proliferation was assessed by staining for phosphohistone
H3 (1:500, Cell signaling). b1 integrin activation was
assessed by labeling with monoclonal anti-human integrin
b1 (HUTS-21, 1:50, BD Pharmingen) as described in
previous studies [9, 18–20]. Activation of focal adhesion
kinase was assessed by phospho-FAK (1:500, Invitrogen)
staining. Total integrin b1 was labeled by monoclonal anti-
integrin b1 (TS2/16, 1:100, American Type Culture Col-
lection). Secondary antibodies included FITC-, Cy3-, or
Cy5-labeled (1:400; Jackson ImmunoResearch Laborato-
ries Inc.), and Alexa 488- or Alexa 568-labeled (1:250;
Invitrogen) goat, donkey, or mouse anti-rat, anti-hamster,
anti-rabbit, anti-goat, or anti-mouse IgG. Examination and
image capture (TIFF images) from immunostained tumor
sections and from in vitro cell cultures were accomplished
using a Fluoview 1000 (Olympus) Laser Point Scanning
Confocal Microscope and an Inverted TE300 Nikon
Fluorescence Microscope as described previously [611].
Areas (number of pixels) with immunostaining greater than
a set threshold were quantified using computer-based
morphometry software (Image-Pro Plus 4.5, Media
Cybernetics, Inc.).
NG2 downregulation by siRNA transfection
Expression of NG2 proteoglycan by human brain micro-
vascular pericytes was downregulated by transfection of
siRNA targeted to NG2 (GCUAUUUAA-
CAUGGUGCUGtt, siRNA ID#: 146147, Ambion).
Downregulation of NG2 expression was quantified by
immunocytochemistry.
Cell proliferation and migration
Seventy-two hours after siRNA transfection, pericyte
numbers were measured by determining the density of
DAPI-positive nuclei per defined area. Migration of peri-
cytes was examined in 24-well transwell plates (8.0-lm
pore size, Costar) via published methods [9].
Vascular network formation in pericyte/endothelial cell
co-cultures
Vascular network formation in three dimensions was
studied by co-culturing HUVECs and pericytes in Matrigel
[21]. Pericytes were pre-treated with NG2-targeting siR-
NA, scrambled siRNA, or GAPDH-targeting siRNA. Ma-
trigel (BD 356231, growth factor reduced, phenol red-free)
was loaded (0.25 ml) in chilled 4-well CultureSlides
(354114, BD) or (0.1 ml) glass bottom microwell dishes
(P35G-1.5-14-C, MatTek), and allowed to gel at 37 C for
8 h. For fluorescence imaging, pericytes and HUVECs
were pre-stained with 4 lM CellTracker Red CMTPX
(Invitrogen) and CellTracker Green CMFDA (5-chlor-
omethylfluorescein diacetate, Invitrogen), respectively, in
basal medium for 30 min, and then incubated overnight in
either PM or EBM. Labeled pericytes and HUVECs were
harvested by trypsinization, resuspended in EBM-2 med-
ium (5 9 104 cells/ml), and mixed at a 1:4 pericyte/HU-
VEC ratio. This mixture (0.5 ml or 2.5 ml) was seeded in
4-well CultureSlides or glass bottom microwell dishes,
respectively. HUVEC/pericyte networks began to form
after 2–4 h. Network formation was evaluated by scanning
confocal microscopy.
Endothelial cell permeability
Permeability of endothelial cell monolayers in vitro was
studied in 24-well transwell plates (0.4-lm pore size,
Costar) using in-contact co-cultures of pericytes and HU-
VECs [22, 23] established on opposite sides of transwell
inserts. Endothelial cells were seeded on the upper surface
of the membrane at a density of 105 cells/ml, while peri-
cytes were seeded on the lower surface of the membrane at
a density of 5 9 104 cells/ml. For non-contact co-cultures,
pericytes were seeded on the bottom of the transwell rather
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than on the lower surface of the membrane. In some cases,
endothelial cell monolayers were used in the absence of
pericyte monolayers (see Fig. 6a). Medium in the lower
chamber contained VEGF (5 ng/ml), and medium in the
upper chamber contained FITC-dextran (0.2 mg/ml,
250 kDa, Sigma) and VEGF (5 ng/ml). After 5 h of incu-
bation, the FITC-dextran content of lower chambers was
determined by absorbance at 494 nm. Purified, soluble,
recombinant NG2 used in these experiments was prepared
according to [9, 24].
Statistical analysis
All results are expressed as mean ± SE. Statistical analy-
ses were performed using the two-tailed t test. P \ 0.05
was considered statistically significant.
Results
Pericyte-specific ablation of NG2 leads to deficits
in tumor blood vessel structure and function
NG2 flox/flox females were crossed with NG2 flox/wt/pdgfrb-Cre
males to generate NG2 flox/flox (control) and NG2 flox/flox/pdgfrb-Cre
(pericyte-NG2ko) progeny. B16F10 melanomas were
established in the brains of these two sets of mice. In
tumors from pericyte-NG2ko mice, we confirmed that NG2
expression is absent from pericytes (Fig. 1). Whereas in
control mice, NG2 is strongly expressed by PDGFRb-
positive pericytes (Fig. 1a, b), in pericyte-NG2ko mice,
NG2 is largely undetectable in these cells (Fig. 1c, d).
Quantification of NG2-positive pixels reveals a 75 %
reduction in NG2 expression in tumors from the pericyte-
NG2ko mice (Fig. 1e). Although NG2 is not expressed by
the B16F10 melanoma cells [11], it is expressed by mac-
rophages [10]. We therefore confirmed the pericyte-spe-
cific ablation of NG2 via immunostaining for the
macrophage marker F4/80. In both control and pericyte-
NG2ko mice, we were able to identify F4/80-positive
macrophages that expressed NG2 (Fig. 1i–n, arrows).
Since pericytes are clearly NG2-negative in pericyte-
NG2ko mice, NG2 expression by macrophages at least
partially accounts for residual NG2 expression in these
mice.
We also were able to determine that ensheathment of
CD31-positive endothelial cells by PDGFRb-positive
pericytes is reduced in tumor vessels in pericyte-NG2ko
mice (Fig. 1f, g). Compared to control mice, endothelial
cells are less well covered by pericytes in pericyte-
NG2ko mice (arrows in G). Quantification of coverage
reveals a 30 % decrease in pericyte ensheathment in the
absence of pericyte NG2 (Fig. 1h). Similar to our
previous findings with tumor blood vessels in germline
NG2 knockout mice [10, 11], this NG2-dependent
decrease in pericyte/endothelial cell interaction leads to
additional structural deficits in the vasculature. In par-
ticular, we noted diminished assembly of the vascular
basal lamina, as revealed by determining the overlap
between CD31 labeling and labeling for the basement
membrane marker collagen IV. Quantification of these
data demonstrates a 30 % decrease in basal lamina
assembly in pericyte-NG2ko mice (Fig. 2a). In addition,
we used comparisons of CD31 staining (all endothelial
cells) and perfused FITC-LEA staining (endothelial cells
in functional vessels) to determine that functional tumor
vessels (vessel patency) are reduced by 40 % in pericyte-
NG2ko mice (Fig. 2b). Structural deficits in pericyte-
NG2ko tumor vessels also resulted in roughly a threefold
increase in leakage of perfused FITC-dextran into the
extravascular space (Fig. 2c). These diminished func-
tional properties of pericyte-NG2ko vessels are reflected
by a sixfold increase in intratumoral hypoxia, as deter-
mined by quantifying retention of the hypoxia probe
pimonidazole (Fig. 2d).
NG2 knockdown inhibits pericyte proliferation
and migration in vitro
In order to elucidate mechanisms that underlie the vascular
deficits observed in tumor vessels in pericyte-NG2ko mice,
we used siRNA methodology to knock down NG2
expression in pericytes in vitro. Compared to transfection
with control siRNA species (Fig. 3a–c), transfection with
NG2-targeted siRNA results in virtually complete loss
(more than 98 %) of NG2 expression by human brain
microvascular pericytes (Fig. 3d, e). Since NG2 expression
is often associated with enhanced cell proliferation and
motility [13], we compared these properties in control
Fig. 1 Pericyte-specific NG2 ablation leads to reduced pericyte
ensheathment of endothelial cells. NG2 proteoglycan (red) is co-
expressed with PDGFRb (green) in pericytes in B16F10 tumor
vessels in control mice (a, b). However, in tumors in pericyte-NG2ko
mice, pericyte expression of NG2 is largely abolished (c, d). Total
NG2 expression (NG2-positive pixels) is reduced by 75 % in tumors
in pericyte-NG2ko mice (e). Pericyte ensheathment of endothelial
cells (f, g) was evaluated by double staining for PDGFRb (green) and
CD31 (blue), allowing determination of PDGFRb/CD31 overlap in z-
stacks of confocal images. Overlap of PDGFRb pixels with CD31
pixels is reduced in pericyte-NG2ko tumor blood vessels (arrows in
g). Quantification reveals a 31 % decrease in pericyte ensheathment
of endothelial cells (h). Macrophages, identified by immunostaining
for F4/80 (green), contribute to the overall level of NG2 expression
(red) in tumors in control mice (i–k, arrows). In tumors in pericyte-
NG2ko mice, NG2 expression is retained by macrophages (l–n,
arrows), but not by pericytes. *P \ 0.05 versus control mice. Scale
bar 40 lm (a–d, f, g), 120 lm (i–n). (Color figure online)
c
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pericytes and pericytes treated with NG2 siRNA. After
siRNA treatment, pericyte numbers in the NG2 siRNA-
treated population are reduced almost threefold compared
to numbers of control siRNA-treated pericytes (Fig. 3a–d,
f). Reduced pericyte numbers could also be due to
increased pericyte apoptosis following NG2 ablation [18,
20], although we did not detect morphological signs of
pericyte apoptosis in this population. Labeling for activated
caspase-3, a more sensitive means of identifying apoptotic
cells, also did not reveal detectable levels of apoptosis in
NG2 siRNA-treated cells (Fig. 3g). In contrast, phospho-
histone H3-positive cells are reduced by 70 % in NG2
siRNA-treated pericytes (Fig. 3h–k), confirming a specific
effect of NG2 ablation on cell proliferation.
Effects of NG2 ablation on pericyte migration were
examined via transwell migration assays. Inclusion of
PDGF-BB in the lower chamber was used to stimulate
migration of pericytes transfected with NG2 siRNA and
control siRNA species. Compared to large numbers of
migratory pericytes in the control groups, pericytes trans-
fected with NG2 siRNA exhibit markedly reduced migra-
tion (Fig. 3l–n). Quantification of cells on the lower side of
the transwell membrane indicates that NG2 knockdown
reduces PDGF-BB-induced pericyte motility by more than
60 % (Fig. 3o).
NG2 knockdown reduces activation of b1 integrin
and focal adhesion kinase signaling in pericytes
The ability of NG2 to activate b1 integrin signaling when
both molecules are expressed in the same cell [18, 20]
suggests a mechanism for explaining the positive effect of
NG2 on pericyte proliferation and motility. To investigate
this possibility, we used the conformationally sensitive b1
integrin antibody HUTS-21 [19] to detect activation of b1
in human pericytes. We also used an antibody against
phosphorylated focal adhesion kinase (phospho-FAK397)
to detect FAK activation downstream of enhanced integrin
signaling. In pericytes treated with control siRNA species,
activated b1 integrin is abundant on pericyte cell surfaces
(Fig. 4a, b). Phosphorylation of FAK is also robust in these
control pericytes. However, NG2 siRNA-mediated knock-
down of pericyte NG2 expression reduces levels of acti-
vated b1 integrin by 60 % (Fig. 4c, d). Phosphorylation of
FAK in NG2-deficient pericytes is also reduced by 40 %
compared to control pericytes (Fig. 4c, e). Compared to the
significant reduction in activated b1 integrin levels in NG2
Fig. 2 Pericyte-specific NG2 ablation leads to structural and func-
tional deficits in tumor blood vessels. Vascular basal lamina
deposition, assessed by staining for type IV collagen associated with
the CD31-positive vascular endothelium, is significantly reduced in
tumor blood vessels of pericyte-NG2ko mice (PC NG2 KO; panel a,
25 % reduction). Tumor vessel patency was evaluated by perfusion of
animals with FITC-LEA, followed by immunostaining of sections for
CD31. Functional vessels are labeled for both FITC-LEA and CD31,
while non-functional vessels are labeled only for CD31. Patency is
reduced by 40 % in tumor vessels in pericyte-NG2ko mice (panel b).
Vessel leakiness was assessed by perfusion of animals with FITC-
dextran, followed by immunostaining of sections for CD31. Leakage
is quantified by measuring FITC-dextran located outside of CD31-
positive blood vessels. Vessels in pericyte-NG2ko mice are almost
threefold leakier than vessels in control mice (panel c). Intratumoral
hypoxia was measured after perfusion of animals with pimonidazole
hypoxia probe and immunostaining of sections with antibody against
pimonidazole. Areas of hypoxia are increased almost sixfold in
pericyte-NG2ko mice (panel d). *P \ 0.05 versus control mice.
Experimental details of these analyses can be found in [10, 11]
Fig. 3 NG2 downregulation inhibits pericyte proliferation and
migration. NG2 expression (red) by human brain microvascular
pericytes is not affected by treatment with negative siRNA (b) or
GAPDH siRNA (c), compared to NG2 expression by control pericytes
(a). However, NG2 expression is largely abolished by treatment with
NG2-targeting siRNA (d). NG2-positive pixels are reduced by 98 %
in pericytes treated with NG2 siRNA (e). In addition, the number of
DAPI-positive pericyte nuclei (blue) is markedly lower (64–70 %
reduction) in NG2 siRNA-treated cultures compared to control
cultures (f), suggestive of reduced proliferation in the absence of
NG2. Immunostaining for activated caspase-3 (red) does not reveal
any evidence of apoptosis in NG2 siRNA-treated cultures (g).
However, immunostaining for phosphohistone H3 (red) demonstrates
a 70 % reduction in mitotic index in NG2 siRNA-treated cultures
compared to control siRNA-treated cultures (h–k). Pericytes treated
with negative siRNA (l) or GAPDH siRNA (m) actively migrate
through 8-lm pores (round circles) in transwell membranes in
response to stimulation with PDGF-BB (20 ng/ml). However, migra-
tion of NG2 siRNA-treated pericytes is markedly reduced under these
conditions (n, o). Pericytes are stained with hematoxylin. Blue =
DAPI. *P \ 0.05 versus negative siRNA, P \ 0.05 versus GAPDH
siRNA. Scale bar 120 lm (a–d, g, l–n), 240 lm (h–j). (Color figure
online)
c
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siRNA-treated pericytes, levels of total b1 integrin are not
markedly changed after treatment with any of the siRNA
species (Fig. 4f–i). These results support the idea that
NG2-dependent activation of b1 integrin signaling (and
subsequent phosphorylation of FAK) is a key mechanism
underlying the ability of NG2 to promote pericyte prolif-
eration and motility.
NG2 knockdown in pericytes diminishes formation
of pericyte/endothelial cell networks
Since soluble, purified NG2 is effective in stimulating the
formation of endothelial networks in vitro [9], we tested
the effect of NG2 knockdown on the ability of pericytes to
interact with endothelial cells to form pericyte/endothelial
Fig. 4 NG2 downregulation in pericytes decreases b1 integrin
activation and downstream phosphorylation of focal adhesion kinase.
To examine molecular mechanisms responsible for diminished
pericyte function after NG2 downregulation, we examined activation
of b1 integrin (mAb HUTS-21, green) and phosphorylation of its
downstream target, focal adhesion kinase (P-Tyr371FAK, red).
Activated b1 integrin and phosphorylated FAK are readily detectable
in pericytes treated with negative siRNA (a) or GAPDH siRNA (b).
However, treatment of pericytes with NG2 siRNA substantially
reduces both b1 integrin activation and FAK phosphorylation (c),
revealing the dependence on NG2 for activation of this signaling
pathway. Measurements of fluorescence intensity demonstrate a 60 %
reduction in activation of b1 integrin and a 40 % reduction in FAK
phosphorylation (d, e). Total expression levels of b1 integrin (mAb
TS2/16; green) in pericytes are not significantly reduced by treatment
with any of the siRNA species (f–i). Blue = DAPI. *P \ 0.05 versus
negative siRNA, P \ 0.05 versus GAPDH siRNA. Scale bar 240 lm
(a–c), 120 lm (f–h). (Color figure online)
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cell networks. Pericytes were treated with control or NG2
siRNA species, then co-cultured with HUVECs in Matri-
gel. Time-lapse imaging at early time points reveals the
movement of both pericytes and HUVECs and the asso-
ciation of the two cell types to form three-dimensional
networks in the Matrigel (Fig. 5). Three-dimensional net-
works containing both endothelial cells and control peri-
cytes are evident after 2–4 h of co-culture (Fig. 5a;
supplemental videoS1). In the case of NG2-deficient peri-
cytes, however, network formation by pericytes and HU-
VECs is significantly retarded at these time points (Fig. 5b;
supplemental videoS2). At 8 h, reduced network formation
is still apparent in co-cultures of endothelial cells with NG2
knockdown pericytes (Fig. 5c–e). Use of CellTracker Red-
labeled pericytes and CellTracker Green-labeled endothe-
lial cells demonstrates the presence of both cell types in 8-h
networks (Fig. 5f, g). Quantification of network formation
at 16 h shows that the average total length of networks at
16 h is reduced 25 % by NG2 knockdown in pericytes
(Fig. 5h).
NG2 knockdown in pericytes reduces activation of b1
integrin in endothelial cells
Soluble, purified NG2 can stimulate b1 integrin activation
in endothelial cells [9]. We therefore examined whether
pericyte cell surface NG2 can also activate b1 integrin
signaling in endothelial cells as a means of altering endo-
thelial cell morphogenesis. After treatment with the various
siRNAs, pericytes were cultured on the lower surface of a
transwell membrane with 0.4-lm-diameter pores. HU-
VECs were cultured on the upper surface of the same
membrane (in-contact model in Fig. 6a). The membrane
physically separates the two cell types and prevents cell
migration across the membrane, but allows cell–cell con-
tact via cellular processes that extend through the mem-
brane pores [25–27]. After immunolabeling, confocal
microscopy permits specific examination of the endothelial
cell monolayer. Most HUVECs strongly express CD31
regardless of pericyte siRNA treatment, and in control-
treated HUVECs activated integrin b1 integrin is often
present on the cell surface along with CD31 (Fig. 6b, c,
arrows). In contrast, after pericyte treatment with NG2
siRNA, levels of activated b1 integrin are reduced and are
poorly co-localized with CD31 on cell surfaces (Fig. 6d–f).
We also used the transwell membrane system to re-
examine b1 integrin activation in endothelial cells treated
with purified, soluble NG2 (see Ref. [9]). Addition of
soluble NG2 to an endothelial monolayer in an endothe-
lium-only model (Fig. 6a) results in significant b1 integrin
activation (Fig. 6g). This result suggests the possibility that
NG2 shed from pericyte surfaces, rather than direct contact
between pericytes and endothelial cells, might be
responsible for the effect on b1 integrin activation seen in
the double-monolayer model. This possibility was tested
via use of a non-contact model in which endothelial cells
were again grown on the upper surface of the transwell
membrane, while pericytes were grown on the bottom of
the transwells instead of on the lower surface of the
membrane (Fig. 6a). In the absence of direct contact
between pericytes and endothelial cells, knockdown of
NG2 has no effect on b1 integrin activation in endothelial
cells (Fig. 6h). Apparently, under these conditions, NG2 is
not shed from pericytes in sufficient quantities to affect
signaling in endothelial cells. Thus, in this format, direct
contact between the two cell populations is required for
NG2-mediated activation of b1 integrin signaling. As a
control, we showed that there were no significant changes
in expression levels of total b1 integrin in endothelial
monolayers after treatment with any of the siRNA species
or soluble NG2 (Fig. 6i–k).
NG2 knockdown in pericytes reduces endothelial
junctions and increases endothelial permeability
Since pericytes are important for stabilizing many proper-
ties of the endothelial lumen, we tested the ability of
control and NG2-deficient pericytes to influence the per-
meability of endothelial monolayers. For this purpose, we
again used transwell membranes with 0.4-lm-diameter
pores, with endothelial monolayers grown on the upper
surface and pericyte monolayers grown on the lower sur-
face (in-contact model, Fig. 6a) [22, 23]. As in the b1
integrin activation experiments, contact between the two
cell types is mediated by cellular processes that extend
through the membrane pores. VEGF was included to
stimulate permeability of the endothelial monolayer, and
FITC-dextran was included in the upper chamber as a
Fig. 5 NG2 downregulation in pericytes retards formation of vascu-
lar networks with endothelial cells. Control pericytes and HUVECs
were co-cultured at a 1:4 pericyte/HUVEC ratio in Matrigel. Initial
signs of network formation are evident as soon as 1 h after the start of
co-culture (a). Networks become increasingly organized between 2
and 4 h after co-culture. Network formation by NG2 siRNA-treated
pericytes and HUVECs is significantly retarded at these same time
points (b). Even after 8 h of co-culture, networks formed by NG2
siRNA-treated pericytes and HUVECs are less extensive than
networks formed by control pericytes and HUVECs (c–e). Fluores-
cence images confirm that vascular networks at 8 h (f, g) are
composed of both endothelial cells (labeled with CellTracker Green
MFDA) and pericytes (labeled with CellTracker Red CMTPX).
Networks containing NG2 knockdown pericytes (g) are again seen to
be less extensive than those containing control pericytes (f). At 16 h
of co-culture, quantification of total network lengths per unit area
reveals that networks containing NG2 knockdown pericytes are 25 %
less extensive than networks containing control pericytes (H).
*P \ 0.05 versus negative siRNA, P \ 0.05 versus GAPDH siRNA.
Scale bar 480 lm (a–b), 240 lm (c–g). (Color figure online)
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means of quantifying permeability. Leakage of FITC-
dextran into the lower chamber through an endothelial cell
monolayer associated with NG2 knockdown pericytes was
increased by 32 % compared to leakage through an endo-
thelial monolayer associated with control pericytes, dem-
onstrating a decrease in barrier function (Fig. 7a). In the
endothelium-only model (Fig. 6a), the permeability of the
monolayer to FITC-dextran is decreased by 24 % after
addition of soluble NG2, confirming the ability of NG2 to
improve the barrier function of the endothelial monolayer
(Fig. 7b). In the non-contact model (Fig. 6a), endothelial
permeability is not affected by NG2 knockdown in peri-
cytes (Fig. 7c).
To investigate the basis for the increased permeability of
endothelial monolayers co-cultured with NG2-deficient
pericytes in the in-contact model, we examined endothelial
monolayers for the expression level and distribution of ZO-
1, an important endothelial junction protein. Interestingly,
the levels of ZO-1 expression and ZO-1 distribution around
endothelial cells are significantly reduced in endothelial
monolayers cultured with NG2-deficient pericytes (Fig. 7d,
e, h), signifying a loss of endothelial junctions in the
absence of pericyte NG2. Also in accord with results from
the endothelial permeability studies, soluble NG2 signifi-
cantly increases ZO-1 expression and co-localization with
CD31 in the endothelium-only model (Fig. 7f, g, i). As
expected, knockdown of NG2 in pericytes elicits no
changes in ZO-1 expression or localization in the non-
contact model (Fig. 7j). To determine whether NG2-neg-
ative tumor vessels in vivo are also characterized by loss of
endothelial junctions, we examined ZO-1 expression in
tumor blood vessels of control and pericyte-NG2ko mice
(Fig. 7k–o). CD31 and ZO-1 localization are well matched
in tumor vessels in control mice (Fig. 7l, m). However,
ZO-1 labeling is absent from portions of CD31-positive
tumor blood vessels in pericyte-NG2ko mice (Fig. 7n, o,
arrows), resulting in a 35 % decrease in co-localization of
ZO-1 and CD31 (Fig. 7k).
Discussion
Throughout the formation, maturation, and maintenance of
microvessels, pericytes and endothelial cells use a variety
of mechanisms to communicate with each other. Endo-
thelial cells produce PDGF-BB, which promotes pericyte
recruitment via activation of PDGFRb [28, 29]. Endothe-
lial cell-derived TGFb is also important for the recruitment
and differentiation of pericytes [30, 31]. Pericytes produce
angiopoietin-1, which activates Tie2 signaling to promote
endothelial cell maturation [32, 33]. In addition, pericyte-
derived vitronectin activates av integrin signaling in
endothelial cells to enhance endothelial survival via
increased expression of the anti-apoptotic protein Bcl-w
[34]. Adding to this list, we demonstrate in this report that
pericyte expression of the NG2 proteoglycan is important
not only for pericyte biology, but also for critical aspects of
pericyte interaction with endothelial cells. Both of these
NG2 functions appear to depend on its ability to activate b1
integrin signaling.
A number of previous studies in our laboratory have
shown that NG2 promotes cell proliferation and motility in
a variety of immature cell types [13]. Although NG2 is a
transmembrane protein, it appears to have limited capa-
bility for independent signal transduction. Instead, via a
physical interaction with b1 integrins [9, 18], NG2 facili-
tates integrin activation that leads to enhanced cell prolif-
eration and motility [20]. The choice between proliferation
and motility is determined at least in part by the phos-
phorylation status of the NG2 cytoplasmic domain. Protein
kinase Ca-mediated phosphorylation at Thr-2256 results in
localization of NG2/b1 integrin complexes to leading edge
lamellipodia of glioma cells, accompanied by enhanced
glioma cell motility. ERK-mediated phosphorylation at
Thr-2314 results in localization of NG2/b1 integrin com-
plexes to apical cell surface microprotrusions, accompa-
nied by enhanced glioma cell proliferation [20]. Our
current in vitro studies with human brain pericytes are
consistent with this model of NG2-dependent b1 integrin
activation. siRNA-mediated knockdown of NG2 expres-
sion in pericytes results in diminished activation of b1
signaling in the NG2-deficient pericytes, as revealed by
labeling with the conformationally dependent b1 antibody
HUTS-21 [19]. Decreased integrin signaling is
Fig. 6 NG2 downregulation in pericytes decreases activation of b1
integrin in endothelial cells. a Three different in vitro culture formats
were used to investigate interactions between human umbilical vein
endothelial cells (HUVEC) and human brain vascular pericytes
(HBVP). HUVECs and pericytes were cultured on opposite sides of a
transwell membrane (in-contact); HUVECs alone were cultured on a
transwell membrane (endothelium-only); HUVECs were cultured on
a transwell membrane, and pericytes were cultured on the well bottom
(non-contact). The in-contact model was used to examine pericyte-
mediated activation of endothelial cell b1. Membranes were immu-
nostained for CD31 (green) and activated b1 integrin (red), and
confocal microscopy was used to examine the endothelial cell
monolayer. CD31 labeling is similar in endothelial cell monolayers
co-cultured with either control (b) or NG2 knockdown pericytes (d).
However, activated b1 integrin is more prominent and more closely
co-localized with CD31 on the surfaces of HUVECs co-cultured with
control pericytes (c) than on HUVECs co-cultured with NG2
knockdown pericytes (e, quantified in f). In the endothelium-only
model, b1 integrin activation is increased by the addition of soluble
NG2 (sNG2) (g). In the non-contact model, activation of b1 integrin
is not affected by treatments with control or NG2 siRNA (h). Total
levels of b1 integrin expression are not affected by siRNA treatment
in any of the three models (i–k). *P \ 0.05 versus GAPDH siRNA
(f). P \ 0.05 versus absence of sNG2 (g). Scale bar 120 lm (b–e).
(Color figure online)
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accompanied by reduced downstream phosphorylation of
FAK. Diminished signaling in this pathway is accompanied
by decreased pericyte proliferation and motility. Although
we did not examine pericyte proliferation or motility
in vivo in the current work, we have previously reported
in vivo evidence for reduced pericyte proliferation and
motility in NG2 null mice. Reduced pericyte proliferation
is observed in NG2 null mice in a retinal hyperoxia model
[12] and in a corneal neovascularization model [35],
leading to abnormal blood vessels in which endothelial
cells are poorly ensheathed by pericytes. Reduced pericyte
motility is seen in NG2 null mice in the corneal neovas-
cularization model, in which NG2 ablation diminishes
pericyte recruitment from limbal vessels to neovessels
within the cornea [12].
In addition to functioning in a cis arrangement with both
NG2 and b1 integrin expressed in the same cell, we sus-
pected that NG2 might also be capable of operating in a
trans mode to activate b1 integrin signaling in closely
apposed cells. This is based on our observation that puri-
fied, soluble NG2 activates b1 signaling in endothelial cells
in vitro, driving endothelial cell morphogenesis and the
formation of vascular networks [9]. This expectation is
borne out in our current work by the finding that NG2
knockdown in a pericyte monolayer reduces b1 integrin
activation in an endothelial cell monolayer growing on the
opposite face of a transwell membrane with 0.4-lm-
diameter pores. A number of studies have demonstrated the
ability of these membranes to prevent cell migration across
the membrane while allowing cell–cell contact between
processes that extend through the pores [25–27, 36, 37].
There are multiple consequences of reduced NG2-depen-
dent b1 signaling in endothelial cells. The impact of peri-
cytes on endothelial cell morphogenesis is decreased, as
shown by the impaired interaction of pericytes with
endothelial cells to generate complex vascular networks
in vitro. Moreover, using the in-contact double-monolayer
model on opposite sides of transwell membranes, we show
that formation of endothelial junctions is reduced by NG2
knockdown in pericytes. This is evidenced by loss of
expression/localization of the junctional molecule ZO-1.
Accordingly, NG2 knockdown in pericytes reduces the
barrier function of the endothelial cell monolayer, as
revealed by increased leakage of FITC-dextran through the
monolayer. The direct involvement of NG2 in improving
the barrier function of the endothelial monolayer is con-
firmed by the ability of purified, soluble NG2 to decrease
FITC-dextran leakage across the monolayer. However,
NG2 does not appear to be shed by pericytes in sufficient
quantities to affect endothelial cell properties in the in-
contact double-monolayer model, since endothelial cell
properties are not affected by pericytes grown with endo-
thelial cells in a non-contact format. Thus, at least in these
models, direct contact between pericytes and endothelial
cells appears to be required for NG2-dependent activation
of b1 integrin signaling and increased junction formation in
endothelial cells.
Impaired interaction of NG2-negative pericytes with
endothelial cells is also seen in our in vivo vascularization
studies. Following exposure to hyperoxia, pathological
blood vessels in the retina are poorly ensheathed by peri-
cytes in the germline NG2 null mouse [12]. Germline
ablation of NG2 also diminishes pericyte ensheathment of
endothelial cells in both mammary tumors [10] and intra-
cranial melanomas [11], leading to a number of vascular
deficits, including decreased basal lamina assembly,
impaired development of both pericytes and endothelial
cells, decreased vessel patency, increased vessel leakiness,
Fig. 7 NG2 knockdown in pericytes reduces endothelial junction
formation and barrier function. In the in-contact model, FITC-dextran
leakage through endothelial monolayers co-cultured with NG2
knockdown pericyte monolayers is greater than leakage through
endothelial monolayers co-cultured with control pericyte monolayers
(a). Treatment with soluble NG2 (sNG2) significantly decreases
FITC-dextran leakage through the endothelial cell monolayer in the
endothelium-only model (b). In the non-contact model, NG2 knock-
down in pericytes has no effect on endothelial permeability (c).
Immunostaining for the endothelial cell junctional protein ZO-1
reveals extensive junction formation in endothelial monolayers co-
cultured with control pericytes in the in-contact model (d). Junction
formation is much less extensive in endothelial monolayers co-
cultured with NG2 knockdown pericytes (e, quantified in h). Addition
of soluble NG2 (sNG2) enhances junction formation between
endothelial cells in the endothelium-only model (F,G, quantified in
i). In the non-contact model, NG2 knockdown in pericytes does not
affect endothelial cell junctions (j). Applying this same methodology
to B16F10 tumor sections, we observed good correspondence
between CD31 (red) and ZO-1 (green) immunolabeling in control
mice (l, m). In contrast, portions of CD31-positive blood vessels in
pericyte-NG2ko mice were deficient in staining for ZO-1 (n,
o arrows; quantified in k). Blue = DAPI. *P \ 0.05 versus negative
siRNA (a), P \ 0.05 versus GAPDH siRNA (a, h). P \ 0.05 versus
absence of sNG2 (b, i). §P \ 0.05 versus control mice (k). Scale bar
120 lm (d–g). Scale bar 60 lm (l–o). (Color figure online)
b
Table 1 Vessel parameters in germline-NG2ko versus pericyte-
NG2ko mice
Parameter Change (compared to control mouse)
Global-NG2ko Pericyte-NG2ko
Pericyte/endothelial overlap 45 % decrease 33 % decrease
Basal lamina assembly 73 % decrease 31 % decrease
Vessel patency 50 % decrease 43 % decrease
Vessel leakiness 400 % increase 270 % increase
Intratumoral hypoxia 2,000 % increase 560 % increase
Various parameters of tumor vessel structure and function are com-
pared between the pericyte-NG2 ko mouse (this report) and the
germline-NG2ko mouse [11]. Deficits in pericyte-NG2ko vessels are
more moderate than changes in germline-NG2ko vessels
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and increased intratumoral hypoxia. However, interpreta-
tion of these results has not been completely straightfor-
ward due to the global nature of the NG2 ablation in the
germline knockout mice. In particular, NG2 is also ablated
in myeloid cells, which are known to be important for
tumor vascularization [38, 39]. The current study therefore
uses pericyte-specific NG2 null mice in order to restrict
NG2 ablation to the pericyte population.
Importantly, reduced pericyte ensheathment of endo-
thelial cells is once again observed in melanoma tumor
vessels in the pericyte-NG2ko mouse, demonstrating that
this NG2-dependent deficit is pericyte autonomous. This
decrease in pericyte/endothelial cell interaction leads to
additional deficits in basal lamina assembly and endothelial
junction formation, accompanied by decreased vessel
patency, increased vessel leakiness, and increased intratu-
moral hypoxia. This is essentially the same spectrum of
vascular defects observed in tumors in the germline NG2
null mouse, emphasizing the importance of NG2-mediated
pericyte/endothelial cell interaction in determining the
structural and functional properties of developing blood
vessels. Nevertheless, it is noteworthy that vascular deficits
detected in the pericyte-NG2ko mouse are generally less
severe than those previously seen in the germline NG2 null
mouse (Table 1). This suggests the possible contribution of
other NG2-positive stromal cell populations to the overall
process of tumor vascularization. Based on our immuno-
histochemical data, macrophages would appear to be the
most likely NG2-positive candidate for this role. Future
studies will examine the properties of tumor blood vessels
in myeloid-specific NG2 null mice, which we are currently
developing in our laboratory. Comparisons of tumor vas-
cularization in pericyte-NG2ko and myeloid-NG2ko mice
will reveal the relative vascular contributions of the NG2
expressed in these two cell populations.
In conclusion, our data show that NG2 plays a dual role
in pericyte biology, contributing not only to pericyte pro-
liferation and motility, but also to pericyte interaction with
endothelial cells. Interestingly, both roles of NG2 depend
on the ability of the proteoglycan to activate b1 integrin
signaling, either via a cis arrangement to activate pericyte
proliferation/motility or via a trans arrangement to activate
endothelial cell morphogenesis. These b1 integrin-depen-
dent roles of NG2 appear to be very important for the
formation of functional tumor vessels, as reflected by
deficits in pericyte/endothelial cell interaction and in vessel
function in pericyte-NG2ko mice.
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